MINNEAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- GelStat Corporation , a pioneer in the development and marketing of next-generation OTC pain relievers, today announced that its first product, GelStat(TM) Migraine, has recently been the subject of increasing media attention as a unique, fast, safe and effective OTC treatment for migraine.
GelStat Migraine has now been featured in 15 separate television news spots in 10 U.S. cities, including Minneapolis, Denver, San Diego, Los Angeles, Des Moines, Chicago, New York, Washington, D.C., Austin and Dallas-Fort Worth.
“Given that migraine afflicts over 30 million Americans -- more than diabetes, asthma and epilepsy combined, and affects one of every four households, it is clearly a topic of intense popular interest,” said Stephen Roberts, M.D., chairman and chief executive officer of GelStat. “Americans presently spend about $2.6 billion a year purchasing more than 600 million packages of OTC headache pain relievers. These older OTC medications work poorly for migraine and have significant side effects. We believe GelStat Migraine is a vastly superior OTC treatment option and are pleased to witness its increasing media recognition, especially since the publication of our initial clinical trial.”
“Looking forward, we see media exposure for GelStat Migraine continuing to increase, both in television and print. We expect to be featured in an additional 30-40 television spots over the next 120 days, and that by the end of the first quarter of 2006 we will have achieved some level of media exposure in every major U.S. city. We expect the publication, within 30 days, of a significant consumer guide to migraine that will feature GelStat Migraine as a uniquely effective OTC treatment. Our experience to date indicates that each of our television appearances has a significant local impact on consumer awareness, and collectively we believe these and other noteworthy pending events will result in substantial revenue growth through the end of 2005 and beyond,” said Dr. Roberts.
The Company has provided clips of several past appearances on its website at: http://www.gelstat.com/inthenews.asp
About GelStat Corporation
GelStat Corporation is dedicated to providing safe and effective OTC treatments for pain and inflammation. GelStat(TM) Migraine, the first product available as a result of these efforts, is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 32 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Americans spend $2.6 billion each year on 600 million units of such products, though they are believed to be effective for only about 25 percent of those with moderate to severe migraine. The initial clinical trial of GelStat Migraine showed it to be effective for 83 percent of those with moderate to severe migraine.
GelStat(TM) Arthritis is the second available product to utilize GelStat’s patent pending formulation. It is provided as a daily use, sublingual dissolving tablet. Arthritis and chronic joint symptoms are among the most common medical complaints in the United States. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans, causing significant, often long-term pain and disability. Typical arthritis medications often provide only marginal relief, and are increasingly associated with frequent and significant side effects such as gastrointestinal bleeding, stroke, heart attack and potentially life-threatening skin reactions. The OTC arthritis medication market is estimated to be approximately $5 billion annually.
In addition to GelStat(TM) Migraine and GelStat(TM) Arthritis, the Company has initiated early marketing efforts for “GelStat(TM) Sinus” and “GelStat(TM) Sleep”, and believes that each of these products performs well and is very effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be “problem sleepers”.
For more information, visit http://www.GelStat.com
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement other than a statement of historical fact should be considered a forward- looking statement. Such forward-looking statements are based on the Company’s current expectations and involve known and unknown risks, uncertainties, or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation and does not intend to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect unanticipated events or developments.
Contact: Stephen C. Roberts, MD Jody Janson Chairman & CEO ISD, Inc. GelStat Corporation 585-232-5440 952-881-4105 jody@istockdaily.cominvestorrelations@gelstat.comhttp://www.istockdaily.com
GelStat Corporation
CONTACT: Stephen C. Roberts, MD Chairman & CEO, GelStat Corporation,+1-952-881-4105, investorrelations@gelstat.com; or Jody Janson of ISD, Inc.+1-585-232-5440, jody@istockdaily.com
Web site: http://www.gelstat.com/
